http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#Head
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#assertion
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#provenance
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#pubinfo
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#assertion
http://purl.obolibrary.org/obo/DOID_2957
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2957
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB08903
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association
http://www.w3.org/2000/01/rdf-schema#label
sirturo is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adults 18 years and older with pulmonary multi drug resistant tuberculosis mdr tb reserve sirturo for use when an effective treatment regimen cannot otherwise be provided administer sirturo by directly observed therapy dot this indication is approved under accelerated approval based on time to sputum culture conversion see clinical studies 14 sirturo is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults 18 years and older with pulmonary multi drug resistant tuberculosis mdr tb reserve sirturo for use when an effective treatment regimen cannot otherwise be provided administer sirturo by directly observed therapy dot 1 2 1 this indication is approved under accelerated approval based on time to sputum culture conversion continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials 1 14 limitations of use 1 14 limitations of use do not use sirturo for the treatment of latent infection due to mycobacterium tuberculosis drug sensitive tuberculosis extra pulmonary tuberculosis infections caused by non tuberculous mycobacteria the safety and efficacy of sirturo in the treatment of hiv infected patients with mdr tb have not been established as clinical data are limited see clinical studies 14
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB08903
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#provenance
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#pubinfo
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#sig
http://purl.org/nanopub/x/hasSignature
Gz5Y7vb3c16ftCWWmPDCMCxkP8qsrfvT+3YKlVThKP+6r5Wgd+MEt72HCv1qck/fyp3vokm18ZetHzTCL/ACYsmqJz42VRGfl5q7wmQwo++pIM6r9J1zVKjKJmkJcYIR0K/Y5j7MUpCxpBrxdcRd1fX2b3nHo39sCm9j2wDwwPQ=
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY
http://purl.org/dc/terms/created
2021-07-03T14:32:24.283+02:00
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAjdwSN3Hxt5638-he0cxYDRLoCy_CE_2DByveWzaiygY
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs